Review article: Targeted screening for hereditary haemochromatosis in high-risk groups

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 1, 2004, Pages 1-14

  Dubois, S ^a   Kowdley, K V ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HFE PROTEIN;

ARTHRITIS; ARTHROPATHY; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; FAMILY; GENE FREQUENCY; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; GENOTYPE; HEART DISEASE; HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IRON OVERLOAD; LIVER DISEASE; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST;

ARTHRITIS; DIABETES MELLITUS; GENETIC SCREENING; HEART DISEASES; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LIVER DISEASES; MEMBRANE PROTEINS; MUTATION; PEDIGREE; RISK FACTORS;

EID: 3142726133     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02024.x     Document Type: Review

References (93)

1. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000; 33: 485-504.
2. Bacon BR, Powell LW, Adams PC, et al. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999; 116: 193-207.
3. Beutler E, Filitti V, Gelbart T, et al. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000; 133: 329-37.
4. Adams PC, Kertesz AE, McLaren CE, et al. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology 2000; 31: 1160-4.
5. McDonnell SM, Hoever A, Gloe D, et al. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med 1999; 107: 30-7.
6. Olynyk JK, Cullen DJ, Aguilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718-24.
7. Burt MJ, George P, Upton JD, et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 1998; 43: 830-6.
8. Wiggers P, Dalhoj J, Kiaer H, et al. Screening for haemochromatosis: prevalence among Danish blood donors. J Intern Med 1991; 230: 265-70.
9. Niederau C, Lange S, Littauer A, et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med 1998; 128: 337-45.
10. Baer DM, Simons JL, Staples RL, et al. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med 1995; 98: 464-8.
11. Leggett BA, Halliday JW, Brown NN, et al. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol 1990; 74: 525-30.
12. Feder JN, Guirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
13. Zakim D, Boyer T. Hepatology. 3 edn. Philadelphia: WB Saunders, 1996.
14. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256-62.
15. Bacon BR, Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997; 92: 784-9.
16. Niederau C, Stremmel W, Strohmeyer GW. Clinical spectrum and management of haemochromatosis. Baillieres Clin Haematol 1994; 7: 881-901.
17. Lin E, Adams PC. Biochemical liver profile in hemochromatosis. A survey of 100 patients. J Clin Gastroenterol 1991; 13: 316-20.
18. Yaouanq JM. Diabetes and haemochromatosis: current concepts, management and prevention. Diabete Metab 1995; 21: 319-29.
19. Stremmel W, Niederau C, Berger M, et al. Abnormalities in estrogen, androgen, and insulin metabolism in idiopathic hemochromatosis. Ann N Y Acad Sci 1988; 526: 209-23.
20. Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: a changing scene. Am J Med 1991; 90: 445-9.
21. Faraawi R, Harth M, Kertesz, A, et al. Arthritis in hemochromatosis. J Rheumatol 1993; 20: 448-52.
22. Schumacher HR, Straka P, Krikker MA, et al. The arthropathy of hemochromatosis. Recent studies. Ann N Y Acad Sci 1988; 526: 224-33.
23. Yang Q, McDonnell SM, Khoury MI, et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998; 129: 946-53.
24. Dabestani A, Child JS, Perloff JK, et al. Cardiac abnormalities in primary hemochromatosis. Ann N Y Acad Sci 1988; 526: 234-44.
25. Candell-Riera J, Lu L, Seres L, et al. Cardiac hemochromatosis: beneficial effects of iron removal therapy. An echocardiographic study. Am J Cardiol 1983; 52: 824-9.
26. Edwards CQ, Kelly T, Ellwein G, et al. Thyroid disease in hemochromatosis. Increased incidence in homozygous men. Arch Intern Med 1983; 143: 1890-3.
27. Fargion S, Mandelli C, Piperno A, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992; 15: 655-9.
28. Adams PC. Population screening for hemochromatosis. Hepatology 1999; 29: 1324-7.
29. Cogswell ME, McDonnell SM, Khoury MJ, et al. Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Ann Intern Med 1998; 129: 971-9.
30. Phatak PD, Guzman G, Woll JE, et al. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med 1994; 154: 769-76.
31. Van der Maas PJ, De Koning HT, Van Ineveld BM, et al. The cost-effectiveness of breast cancer screening. Int J Cancer 1989; 43: 1055-60.
32. Provenzale D. Cost-effectiveness of screening the average-risk population for colorectal cancer. Gastrointest Endosc Clin N Am 2002; 12: 93-109.
33. Smith WJ. The cost-effectiveness of cervical screening. Curr Opin Obstet Gynecol 1999; 11: 83-5.
34. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 2000; 132: 261-9.
35. Sham RL, Raubertas RF, Braggins C, et al. Asymptomatic hemochromatosis subjects: genotypic and phenotypic profiles. Blood 2000; 96: 3707-11.
36. Murtagh LJ, Whiley M, Wilson S, et al. Unsaturated iron binding capacity and transferrin saturation are equally reliable in detection of HFE hemochromatosis. Am J Gastroenterol 2002; 97: 2093-9.
37. Phatak PD, Sham RL, Raubertas RF, et al. Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med 1998; 129: 954-61.
38. Stave GM, Mignogna JJ, Powell GS, et al. Evaluation of a workplace hemochromatosis screening program. Am J Prev Med 1999; 16: 303-6.
39. Adams PC. Nonexpressing homozygotes for C282Y hemochromatosis: minority or majority of cases? Mol Genet Metab 2000; 71: 81-6.
40. Pietrangelo A. Non-HFE hemochromatosis. Hepatology 2004; 39: 21-9.
41. Phatak PD, Ryan DH, Cappuccio J, et al. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis 2002; 29: 41-7.
42. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001; 36: 1108-15.
43. Beutler E, Felitti V, Koziol J, et al. Penetrance of 845G → A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211-8.
44. Ioannou GN, Kowdley KV. In search of vulcan: where are all the iron men (and women)? Gastroenterology 2002; 123: 948-50; discussion 950.
45. Andersen R, Rolf T, Tybjaerg-Hansen A, et al. Hemochomatosis mutations in the general population: iron overload progression rate. Blood 2004; 103: 2914-9.
46. Olynyk J, Hagan S, Cullen D, et al. Evolution of untreated hereditary hemochomatosis in the Brusselton population: a 17-year study. Mayo Clin Proc 2004; 79: 309-13.
47. McLaren CE, Barton JC, Adams PC, et al. Hemochromatosis and iron overload screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci 2003; 325: 53-62.
48. George DK, Evans RM, Crofton RW, et al. Testing for haemochromatosis in the diabetic clinic. Ann Clin Biochem 1995; 32: 521-6.
49. Phelps G, Chapman I, Hall P, et al. Prevalence of genetic haemochromatosis among diabetic patients. Lancet 1989; 2: 233-4.
50. Czink E, Tamas G. Screening for idiopathic hemochromatosis among diabetic patients. Diabetes Care 1991; 14: 929-30.
51. Turnbull AJ, Michison HC, Peason RT, et al. The prevalence of hereditary haemochromatosis in a diabetic population. QJM 1997; 90: 271-5.
52. O'Brien T, Barrett B, Murray DM, et al. Usefulness of biochemical screening of diabetic patients for hemochromatosis. Diabetes Care 1990; 13: 532-4.
53. Dinneen SF, Silverberg J, Batts K, et al. Liver iron stores in patients with non-insulin-dependent diabetes mellitus. Mayo Clin Proc 1994; 69: 13-5.
54. Dubois-Laforgue D, Caillat-Zucman S, Djilali-Saiah I, et al. Mutations in HFE, the hemochromatosis candidate gene, in patients with NIDDM. Diabetes Care 1998; 21: 1371-2.
55. Frayling T, Ellard S, Grove J, et al. C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes. Lancet 1998; 351: 1933-4.
56. Sampson MJ, Williams T, Heyburn PJ, et al. Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes. J Lab Clin Med 2000; 135: 170-3.
57. Braun J, Donner H, Flock K, et al. Hereditary haemochromatosis mutations (HFE) in patients with type II diabetes mellitus. Diabetologia 1998; 41: 983-4.
58. Fernandez-Real JM, Vendrell J, Baiget M, et al. C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes. Diabetes Care 1999; 22: 525-6.
59. Florkowski CM, George PM, Willis JA, et al. Haemochromatosis gene mutations Cys282Tyr and His63Asp are not increased in type 2 diabetic patients compared with the Canterbury (New Zealand) general population. Diabetes Res Clin Pract 1999; 43: 199-203.
60. Kwan T, Leber B, Ahuja S, et al. Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene. Clin Invest Med 1998; 21: 251-7.
61. Salonen JT, Tuomainen TP, Kontula K. Role of C282Y mutation in haemochromatosis gene in development of type 2 diabetes in healthy men: prospective cohort study. BMJ 2000; 320: 1706-7.
62. Moczulski DK, Grzeszczak W, Gawlik B. Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care 2001; 24: 1187-91.
63. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001; 358: 1405-9.
64. Li J, Zhu Y, Singal DP. HFE gene mutations in patients with rheumatoid arthritis. J Rheumatol 2000; 27: 2074-7.
65. Willis G, Scott DG, Jennings BA, et al. HFE mutations in an inflammatory arthritis population. Rheumatology (Oxford) 2002; 41: 176-9.
66. Olynyk J, Hall P, Ahern M, et al. Screening for genetic haemochromatosis in a rheumatology clinic. Aust N Z J Med 1994; 24: 22-5.
67. Mahon NG, Coonar AS, Jeffrey S, et al. Haemochromatosis gene mutations in idiopathic dilated cardiomyopathy. Heart 2000; 84: 541-7.
68. Rosenqvist M, Hultcrantz R. Prevalence of a haemochromatosis among men with clinically significant bradyarrhythmias. Eur Heart J 1989; 10: 473-8.
69. Herrera JL. Abnormal liver enzyme levels. Clinical evaluation in asymptomatic patients. Postgrad Med 1993; 93: 119-20.
70. Bhavnani M, Lloyd D, Bhattacharya A, et al. Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase. Gut 2000; 46: 707-10.
71. Moodie SJ, Ang L, Stenner JM, et al. Testing for haemochromatosis in a liver clinic population: relationship between ethnic origin. HFE gene mutations, liver histology and serum iron markers. Eur J Gastroenterol Hepatol 2002; 14: 223-9.
72. Bacon BR, Olynyk JK, Brunt EM, et al. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999; 130: 953-62.
73. Hezode C, Cazeneuve C, Coue O, et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999; 31: 979-84.
74. Thorburn D, Curry G, Spooner R, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002; 50: 248-52.
75. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999; 116: 127-34.
76. Negro F, Sammi K, Rubbia-Brandt L, et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virology 2000; 60: 21-7.
77. Smith BC, Gorve J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998; 27: 1695-9.
78. Piperno A, Vergani A, Malosio I, et al. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Hepatology 1998; 28: 1105-9.
79. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999; 116: 127-34.
80. Tung BY, Emond MJ, Bronner MP, et al. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003; 124: 318-26.
81. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 1661-9.
82. George DK, Goldwurm S, MacDonald G, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-8.
83. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-9.
84. Chitturi S, Weltman M, Farrell G, et al. HFE mutations, hepatic iron, and fibrosis: Ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142-9.
85. Bugianese E, Manzini P, Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179-87.
86. Grove J, Daly AK, Burt AD, et al. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut 1998; 43: 262-6.
87. Lauret E, Rodriguez M, Gonzales S, et al. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 1016-21.
88. Tavill A. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 1321.
89. Adams PC, Walker AP, Acton RT. A primer for predicting risk of disease in HFE-linked hemochromatosis. Genet Test 2001; 5: 311-6.
90. Adams PC, Kertesz AE. Human leukocyte antigen typing of siblings in hereditary hemochromatosis: a cost approach. Hepatology 1992; 15: 263-8.
91. Powell LW, Summers KM, Board PG, et al. Expression of hemochromatosis in homozygous subjects. Implications for early diagnosis and prevention. Gastroenterology 1990; 98: 1625-32.
92. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343: 1529-35.
93. Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology 1995; 22: 1720-7.